Back to Search
Start Over
Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab.
- Source :
- Journal of Dermatology; Feb2016, Vol. 43 Issue 2, p210-214, 5p
- Publication Year :
- 2016
-
Abstract
- Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab-associated adverse events include organ-specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin-dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab-related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 03852407
- Volume :
- 43
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Journal of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 112505901
- Full Text :
- https://doi.org/10.1111/1346-8138.13028